弥漫大B细胞淋巴瘤CD5表达与临床病理特征及疗效关系的研究  

Relation between CD5 expression and the clinicopathologic features and therapeutic effect of diffuse large B-cell lymphoma

作　　者：柳喜洋[1] 宋波 张蕾[1] 张明智[1] 汪变红[1] 马阳阳[1] 胡腾鹏[1] 

机构地区：[1]郑州大学第一附属医院肿瘤内科,河南郑州450052 [2]信阳市中心医院肿瘤内科,河南信阳464000

出　　处：《中华肿瘤防治杂志》2013年第3期217-220,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:检测CD5蛋白在弥漫大B细胞淋巴瘤(DLBCL)的表达情况,并探讨CD5表达与临床病理特征及疗效的关系。方法:采用免疫组化方法(ElivisionTM法)检测232例患者中CD5蛋白的表达,回顾性研究CD5阳性表达DLBCL与CD5阴性表达DLBCL患者的临床病理特征及化疗效果,运用χ2检验比较两者差异。结果:232例DLBCL患者中,CD5阳性表达率19.8%(46/232)。DLBCL中,CD5表达与年龄(χ2=61.061,P=0.001)、性别(χ2=92.115,P=0.001)、分期(χ2=47.508,P=0.001)、KPS评分(χ2=42.178,P=0.001)、B症状(发热、乏力、盗汗和消瘦,χ2=56.344,P=0.001)、血清LDH水平(χ2=33.341,P=0.001)以及侵犯部位(χ2=78.123,P=0.001)相关;而与血清β2-MG水平无关,χ2=2.495,P=0.138。46例CD5表达阳性的患者中,6例化疗有效,有效率为13.0%(6/46);而186例CD5表达阴性DLBCL患者中,131例患者化疗有效,有效率为70.4%(131/186)。两者比较差异有统计学意义,χ2=50.227,P<0.05。结论:CD5阳性表达的DLBCL好发于老年女性,侵袭性高;CD5阳性表达DLBCL患者比CD5阴性表达的患者疗效差。OBJECTIVE： To test the expression of the CD5 protein in the diffuse large B-cell Lymphoma（DLBCL）, and analyze the relation between the expression of the CD5 protein and the clinicopatbologic features and therapeutic effect of DLBCL. METHODS： Using immunohistochemical methods （ElivisionTM Method）the CD5 protein expression was detec- ted and the clinicopathologic features and therapeutic effect of DLBCL were studied retrospectively. X^2 test was used to compare the differences between them. RESULTS： In all the 232 DLBCL patients, the positive rate of CD5 was 19.8% （46/232）. In DLBCL , CDS-positive expression was related to age（X^2 = 61. 061, P = 0. 001）, sex （ 2 = 92. 115, P = 0. 001） ,stage （X^2 =47. 508,P=0. 001） ,KPS score （X^2 =42. 178,P=0. 001） ,B symptoms （fever ,fatigue ,night swea- ting, marasmus,X^2 = 56. 344, P = 0.001 ）, serum lactate dehydrogenase （LDH） level （X^2 = 33.341, P = 0. 001 ）, the inva- ding sites （X^2= 78. 123, P= 0. 001）. There were significant differences among them, but was not associated with the serum level of β2-MG, X^2= 2. 495,P= 0. 138. Of all the 46 CDS-positive expression DLBCL, 6 patients reached PR, CRu or CR, the therapeutic effective rate was 13.0% （6/46）, while of the 186 patients with CD5-negative expression DLBCL, β1 pa- tients reached PR,CRu or CR , the therapeutic effective rate was 70.4% （131/186）. There was a significant difference be- tween them （X^2= 50. 227,P〈0.05）. CONCLUSIONS： DLBCLs with CD5 positive expression are dominated in elderly fe- male,and more aggressive. DLBCL with CD5 positive expression has poorer therapeutic effect compared to CD5 negative expression.

关 键 词：淋巴瘤 B细胞 CD5 临床病理特征 疗效 免疫组织化学 

分 类 号：R733.1[医药卫生—肿瘤]